Stéphane Oudard
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 228
- Prostate Cancer Treatment and Research 218
- Oncology 275
- Cancer Immunotherapy and Biomarkers 102
- Cancer Treatment and Pharmacology 75
- Co-authors
- Thomas E. Hutson (21 shared papers)Sylvie Négrier (28 shared papers)Ronald M. Bukowski (20 shared papers)Robert J. Motzer (29 shared papers)Cezary Szczylik (24 shared papers)Bernard Escudier (78 shared papers)Robert A. Figlin (14 shared papers)Piotr Tomczak (10 shared papers)
- Journals
- Journal of Clinical Oncology (181 papers)Annals of Oncology (70 papers)European Journal of Cancer (23 papers)The Journal of Urology (20 papers)Clinical Genitourinary Cancer (19 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Stéphane Oudard
586 papers receiving 38.1k citations
Stéphane Oudard's Hit Papers
Peers
Comparison fields: 5 of 148
- Pulmonary and Respiratory Medicine 27.5k
- Cancer Research 12.0k
- Oncology 13.8k
- Molecular Biology 16.5k
- Radiology, Nuclear Medicine and Imaging 4.9k
Countries citing papers authored by Stéphane Oudard
This map shows the geographic impact of Stéphane Oudard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Oudard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Oudard more than expected).
Fields of papers citing papers by Stéphane Oudard
This network shows the impact of papers produced by Stéphane Oudard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Oudard. The network helps show where Stéphane Oudard may publish in the future.
Co-authors
The 25 scholars most cited alongside Stéphane Oudard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 618 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4471 |
| 2 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4338 |
| 3 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 3804 |
| 4 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Hit paper breakdown → | 2010 | 2397 |
| 5 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2339 |
| 6 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1711 |
| 7 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 903 |
| 8 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 868 |
| 9 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 864 |
| 10 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 542 |
| 11 | 2009 | 455 | |
| 12 | Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer Hit paper breakdown → | 2015 | 356 |
| 13 | 2007 | 337 | |
| 14 | Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Hit paper breakdown → | 2015 | 315 |
| 15 | 2007 | 311 | |
| 16 | Bone health in cancer: ESMO Clinical Practice Guidelines Hit paper breakdown → | 2020 | 294 |
| 17 | 2013 | 284 | |
| 18 | 2017 | 263 | |
| 19 | 2017 | 252 | |
| 20 | 2011 | 249 |
About Stéphane Oudard
Stéphane Oudard is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 618 papers that have together received 38.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (228 papers), Prostate Cancer Treatment and Research (218 papers), Renal and related cancers (103 papers), Cancer Immunotherapy and Biomarkers (102 papers), Cancer Genomics and Diagnostics (101 papers), Radiopharmaceutical Chemistry and Applications (94 papers), Cancer Treatment and Pharmacology (75 papers) and Bladder and Urothelial Cancer Treatments (56 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (27.5k citations), Cancer Research (12.0k citations), Oncology (13.8k citations), Molecular Biology (16.5k citations) and Radiology, Nuclear Medicine and Imaging (4.9k citations). Stéphane Oudard has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Thomas E. Hutson, Sylvie Négrier, Ronald M. Bukowski, Robert J. Motzer, Cezary Szczylik, Bernard Escudier, Robert A. Figlin, Piotr Tomczak, M. Dror Michaelson and Christine Théodore. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, The Journal of Urology and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.